iRhythm Technologies, Inc.

Equities

IRTC

US4500561067

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 21:00:00 06/09/2024 BST			5-day change	1st Jan Change
67.20 ^USD	+3.05%		-5.19%	-37.22%

09-04	Transcript : IRhythm Technologies, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 03:20 PM
09-04	IRhythm Technologies Signs License Agreement With BioIntelliSense for Multiparameter Sensor Technology	MT

Irhythm Technologies, Inc. Provides Earnings Guidance for the Year 2024

August 01, 2024 at 09:05 pm

iRhythm Technologies, Inc. provided earnings guidance for the year 2024. The company projects revenue for the full year 2024 to grow approximately 18% to 20% compared to prior year results, ranging from approximately $580 million to $590 million.

Latest news about iRhythm Technologies, Inc.

Transcript : IRhythm Technologies, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 03:20 PM	09-04
IRhythm Technologies Signs License Agreement With BioIntelliSense for Multiparameter Sensor Technology	09-04	MT
IRhythm Technologies, Inc. Reaffirms Earnings Guidance for the Year 2024	09-04	CI
IRhythm Technologies, Inc. Announces Results of GUARD-AF Trial	09-01	CI
IRhythm Technologies Commercially Rolls out Zio Monitor, Zio LTCM ECG Service in Four European Countries	08-29	MT
Needham Adjusts iRhythm Technologies' PT to $119 From $138, Keeps Buy Rating	08-02	MT
Truist Adjusts iRhythm Technologies' PT to $117 From $134, Keeps Buy Rating	08-02	MT
Oppenheimer Adjusts iRhythm Technologies Price Target to $145 From $165, Maintains Outperform Rating	08-02	MT
IRhythm Technologies Appoints Daniel Wilson as Finance Chief	08-02	MT
IRhythm Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-01	CI
Earnings Flash (IRTC) IRHYTHM Reports Q2 Revenue $148M, vs. Street Est of $146.2M	08-01	MT
Earnings Flash (IRTC) IRHYTHM Posts Q2 Loss $-0.61, vs. Street Est of $-0.88	08-01	MT
Transcript : IRhythm Technologies, Inc., Q2 2024 Earnings Call, Aug 01, 2024	08-01
IRhythm Technologies, Inc. Appoints Daniel Wilson as Principal Financial Officer, Effective as of August 31, 2024	08-01	CI
IRhythm Technologies, Inc. Announces Chief Financial Officer Transition, Effective August 31, 2024	08-01	CI
Irhythm Technologies, Inc. Provides Earnings Guidance for the Year 2024	08-01	CI
Truist Lowers Price Target on iRhythm Technologies to $134 From $145, Maintains Buy Rating	07-16	MT
Morgan Stanley Cuts Price Target on iRhythm Technologies to $130 From $135, Keeps Overweight Rating	07-15	MT
IRhythm Technologies Shares Rise After Upgrade From Wolfe Research	06-20	MT
Wolfe Research Upgrades iRhythm Technologies to Outperform From Peer Perform, Price Target is $115	06-20	MT
IRhythm Technologies, Inc. Achieves Significant Operational Milestone with Launch of Initial Phase of Manufacturing Automation	06-17	CI
Transcript : IRhythm Technologies, Inc. Presents at The 44th Annual William Blair Growth Stock Conference, Jun-05-2024 11:20 AM	06-05
Needham Adjusts iRhythm Technologies' PT to $138 From $137, Says 'Strong' Q1 Revenue Growth Should Continue; Keeps Buy Rating	05-03	MT
Transcript : IRhythm Technologies, Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Earnings Flash (IRTC) IRHYTHM Posts Q1 Revenue $131.9M, vs. Street Est of $128.4M	05-02	MT

Chart iRhythm Technologies, Inc.

Duration

Period

More charts

Company Profile

iRhythm Technologies, Inc. is a digital health care company, which creates solutions that detect, predict, and prevent disease. The Company designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. It offers three Zio System options: the Zio Monitor System, the Zio XT System, and the Zio AT System. It offers its Zio ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry monitoring services (Zio Services), using its Zio Systems. The Zio Monitor System is a prescription-only, remote ECG monitoring system that consists of a patch ECG monitor (the Zio Monitor patch) that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period.

Employees

2,000

Sector

Advanced Medical Equipment & Technology

Calendar

10/09/2024 - Baird Global Healthcare Conference

Related indices

Russell 2000

More about the company